A recent study indicates that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who stop traditional diet and exercise plans.
Research printed in a prominent health publication demonstrates that while obese individuals can lose about a fifth of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"People using these medications should be cognizant of the danger of quick rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass within about 18 months.
Comparing Approaches
The study, which examined dozens of studies involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
Researchers note that people who lose weight through diet and exercise usually experience a slower weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Nutrition scientists believe the way of the drugs accounts for the amplified regain.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' results in hunger is uncontrolled, making excessive eating much more probable."
A Lifelong Issue?
Health authorities suggest the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Professionals argue that, due to the significant potential of relapse, the treatment should be considered life-long.
This perspective is supported by pharmaceutical companies, who say that the results "highlight the persistent nature of obesity," akin to managing diseases like hypertension.
User Testimonies
Users who have discontinued the medication describe a sudden return of cravings.
"I experienced a switch activating and you're instantly extremely hungry," described an individual.
This difficulty is worsened if users have not developed permanent dietary or behavioural changes during treatment.
Widespread Use
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is higher among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, researchers caution that while these medications are powerful tools for weight loss, they are not a permanent solution and lasting health benefits hinges on integrated behavioural support.
